[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593415":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":12,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":12,"id":54,"slug":12,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":12,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":12,"enrollmentInfo":61,"targetDuration":12,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":36,"whyStopped":12,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,13,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Normal fasting guidelines and not taking GLP1-RAs","NO_INTERVENTION","Patients who are not taking GLP1 RAs (Receptor Agonists) and who will abide by the normal fasting guidelines",null,{"label":14,"type":10,"description":15,"interventionNames":12},"Normal fasting guidelines with GLP1-RAs","Patients who are taking GLP1 RAs (Receptor Agonists) for either diabetes or weight loss management who will abide by normal fasting guidelines",{"label":17,"type":18,"description":19,"interventionNames":20},"Modified fasting guidelines with GLP1-RAs","EXPERIMENTAL","Patients who are prescribed and taking GLP1 RAs (Receptor Agonists) for either diabetes or weight loss management who follow the modified fasting guidelines. Modified fasting consists of a full-liquid diet 48 hours prior to the procedures, clear liquid diet 24 hours prior to their procedure, and nothing by mouth (NPO) after midnight on the day of their procedure.",[21],"Other: Modified Fasting Guidelines",[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":12},"Modified Fasting Guidelines","Patients will follow a full-liquid diet 48 hours prior to their procedure, clear liquid diet 24 hours prior to their procedure, and nothing by mouth (NPO) after midnight on the day of their procedure",[17],[28],{"name":29,"role":30,"phone":31,"phoneExt":12,"email":32},"Krishnan Ramanujan, MD","CONTACT","507-422-4898","ramanujan.krishnan@mayo.edu",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-92.4699,44.02163,{"lat":46,"lon":45},[49],{"name":29,"role":30,"phone":31,"phoneExt":12,"email":32},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Krishnan Ramanujan","Principal Investigator","100593415",false,"NCT07006142","Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists","Inclusion Criteria:\n\n* Patients undergoing elective upper endoscopy with gastroenterology team\n\nExclusion Criteria:\n\n* Urgent or emergent procedure\n* Inclusion of colonoscopy or antegrade small bowel enteroscopy in planned procedure\n* Upper GI barium study performed in past 24 hours.\n* Gastroparesis\n* Achalasia\n* Pancreatitis\n* Use of outpatient pro-motility medications\n* Patient refusal\n* Inability for patient to provide own consent","ALL","18 Years",{"count":62,"type":63},150,"ESTIMATED","INTERVENTIONAL",[66],"NA","The aim of this study is to determine whether a modified fasting protocol can reduce the potential risk of aspiration for patients currently prescribed GLP1-RAs.",[69,70],"Upper Endoscopy","GLP1-R-related Disease",[72,73],"GLP1 receptor agonists","upper endoscopy","2026-06-01",{"date":76,"type":77},"2026-06-03","ACTUAL",{"date":79,"type":77},"2025-08-01",{"date":81,"type":63},"2026-08-30",{"name":5,"class":6},1]